The multiple facets of glucocorticoid action in rheumatoid arthritis

Ulrike Baschant, Nancy E Lane, Jan Tuckermann

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Glucocorticoids have potent anti-inflammatory effects and have been used to treat patients with rheumatoid arthritis for more than 60 years. However, severe adverse effects of glucocorticoid treatment, including loss of bone mass and increased risk of fractures, are common. Data from studies of glucocorticoid-mediated gene regulation, which utilized conditional knockout mice in animal models of arthritis or glucocorticoid-induced osteoporosis, have substantially increased our understanding of the mechanisms by which glucocorticoids act via the glucocorticoid receptor. Following glucocorticoid binding, the receptor regulates gene expression either by interacting with DNA-bound transcription factors as a monomer or by binding directly to DNA as a dimer. In contrast to the old hypothesis that transrepression mechanisms involving monomeric glucocorticoid receptor actions were responsible for the anti-inflammatory effects of glucocorticoids, whereas dimeric glucocorticoid receptor binding resulted in adverse effects, data from animal models have shown that the anti-inflammatory and adverse effects of glucocorticoids are mediated by both monomeric and dimeric glucocorticoid receptor binding. This improved knowledge of the molecular mechanisms that underlie the beneficial and adverse effects of glucocorticoid therapy might lead to the development of rationales for novel glucocorticoid receptor ligands that could potentially have anti-inflammatory efficacy without adverse effects on bone.

Original languageEnglish (US)
Pages (from-to)645-655
Number of pages11
JournalNature Reviews Rheumatology
Volume8
Issue number11
DOIs
StatePublished - Nov 2012

Fingerprint

Glucocorticoids
Rheumatoid Arthritis
Glucocorticoid Receptors
Anti-Inflammatory Agents
Animal Models
Bone and Bones
DNA
Knockout Mice
Osteoporosis
Arthritis
Transcription Factors
Ligands
Gene Expression
Therapeutics
Genes

ASJC Scopus subject areas

  • Rheumatology

Cite this

The multiple facets of glucocorticoid action in rheumatoid arthritis. / Baschant, Ulrike; Lane, Nancy E; Tuckermann, Jan.

In: Nature Reviews Rheumatology, Vol. 8, No. 11, 11.2012, p. 645-655.

Research output: Contribution to journalArticle

Baschant, Ulrike ; Lane, Nancy E ; Tuckermann, Jan. / The multiple facets of glucocorticoid action in rheumatoid arthritis. In: Nature Reviews Rheumatology. 2012 ; Vol. 8, No. 11. pp. 645-655.
@article{efe316b2c1ef4ffbb3479c0b14e319ff,
title = "The multiple facets of glucocorticoid action in rheumatoid arthritis",
abstract = "Glucocorticoids have potent anti-inflammatory effects and have been used to treat patients with rheumatoid arthritis for more than 60 years. However, severe adverse effects of glucocorticoid treatment, including loss of bone mass and increased risk of fractures, are common. Data from studies of glucocorticoid-mediated gene regulation, which utilized conditional knockout mice in animal models of arthritis or glucocorticoid-induced osteoporosis, have substantially increased our understanding of the mechanisms by which glucocorticoids act via the glucocorticoid receptor. Following glucocorticoid binding, the receptor regulates gene expression either by interacting with DNA-bound transcription factors as a monomer or by binding directly to DNA as a dimer. In contrast to the old hypothesis that transrepression mechanisms involving monomeric glucocorticoid receptor actions were responsible for the anti-inflammatory effects of glucocorticoids, whereas dimeric glucocorticoid receptor binding resulted in adverse effects, data from animal models have shown that the anti-inflammatory and adverse effects of glucocorticoids are mediated by both monomeric and dimeric glucocorticoid receptor binding. This improved knowledge of the molecular mechanisms that underlie the beneficial and adverse effects of glucocorticoid therapy might lead to the development of rationales for novel glucocorticoid receptor ligands that could potentially have anti-inflammatory efficacy without adverse effects on bone.",
author = "Ulrike Baschant and Lane, {Nancy E} and Jan Tuckermann",
year = "2012",
month = "11",
doi = "10.1038/nrrheum.2012.166",
language = "English (US)",
volume = "8",
pages = "645--655",
journal = "Nature reviews. Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - The multiple facets of glucocorticoid action in rheumatoid arthritis

AU - Baschant, Ulrike

AU - Lane, Nancy E

AU - Tuckermann, Jan

PY - 2012/11

Y1 - 2012/11

N2 - Glucocorticoids have potent anti-inflammatory effects and have been used to treat patients with rheumatoid arthritis for more than 60 years. However, severe adverse effects of glucocorticoid treatment, including loss of bone mass and increased risk of fractures, are common. Data from studies of glucocorticoid-mediated gene regulation, which utilized conditional knockout mice in animal models of arthritis or glucocorticoid-induced osteoporosis, have substantially increased our understanding of the mechanisms by which glucocorticoids act via the glucocorticoid receptor. Following glucocorticoid binding, the receptor regulates gene expression either by interacting with DNA-bound transcription factors as a monomer or by binding directly to DNA as a dimer. In contrast to the old hypothesis that transrepression mechanisms involving monomeric glucocorticoid receptor actions were responsible for the anti-inflammatory effects of glucocorticoids, whereas dimeric glucocorticoid receptor binding resulted in adverse effects, data from animal models have shown that the anti-inflammatory and adverse effects of glucocorticoids are mediated by both monomeric and dimeric glucocorticoid receptor binding. This improved knowledge of the molecular mechanisms that underlie the beneficial and adverse effects of glucocorticoid therapy might lead to the development of rationales for novel glucocorticoid receptor ligands that could potentially have anti-inflammatory efficacy without adverse effects on bone.

AB - Glucocorticoids have potent anti-inflammatory effects and have been used to treat patients with rheumatoid arthritis for more than 60 years. However, severe adverse effects of glucocorticoid treatment, including loss of bone mass and increased risk of fractures, are common. Data from studies of glucocorticoid-mediated gene regulation, which utilized conditional knockout mice in animal models of arthritis or glucocorticoid-induced osteoporosis, have substantially increased our understanding of the mechanisms by which glucocorticoids act via the glucocorticoid receptor. Following glucocorticoid binding, the receptor regulates gene expression either by interacting with DNA-bound transcription factors as a monomer or by binding directly to DNA as a dimer. In contrast to the old hypothesis that transrepression mechanisms involving monomeric glucocorticoid receptor actions were responsible for the anti-inflammatory effects of glucocorticoids, whereas dimeric glucocorticoid receptor binding resulted in adverse effects, data from animal models have shown that the anti-inflammatory and adverse effects of glucocorticoids are mediated by both monomeric and dimeric glucocorticoid receptor binding. This improved knowledge of the molecular mechanisms that underlie the beneficial and adverse effects of glucocorticoid therapy might lead to the development of rationales for novel glucocorticoid receptor ligands that could potentially have anti-inflammatory efficacy without adverse effects on bone.

UR - http://www.scopus.com/inward/record.url?scp=84868506206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868506206&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2012.166

DO - 10.1038/nrrheum.2012.166

M3 - Article

VL - 8

SP - 645

EP - 655

JO - Nature reviews. Rheumatology

JF - Nature reviews. Rheumatology

SN - 1759-4790

IS - 11

ER -